What Happened to Compounded Tirzepatide? 2026 FDA Status Explained

VirtualCareFinder may earn a commission when you visit a provider through our links.

Through most of 2023 and 2024, patients could get compounded tirzepatide for $150 to $250 per month through platforms like Mochi Health, Henry Meds, and Brello Health. It was the same active ingredient as Zepbound, prepared by licensed compounding pharmacies and accessible without insurance. Then, on March 19, 2025, the FDA officially resolved the tirzepatide shortage. Within weeks, platforms started pausing or ending their compounded tirzepatide programs. Reddit threads filled up with "what happened to my medication?" questions, and patients found themselves scrambling for alternatives. This post explains exactly what changed, which legal pathways still exist in 2026, which platforms still offer compounded tirzepatide, and what to do if yours stopped. Browse GLP-1 providers available in your state to see current options.

Quick-Answer Comparison

Before diving into the details, here is a side-by-side look at where the four main options stand in 2026.

FDA Timeline: What Changed and When

The story of compounded tirzepatide is a regulatory timeline spanning three years. Here is the sequence of events that brought us to where we are today.

What "Medical Necessity" Compounding Means in Practice

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a licensed pharmacist can compound a drug that is not commercially available in the exact form needed for a specific patient, provided a physician documents a clinical reason. For tirzepatide after the March 2025 shortage resolution, this framework is the only remaining legal path for 503A compounding. Here is what it requires in practice:

• Physician documentation is mandatory.A physician must document in writing why commercially available Zepbound does not meet the specific patient's needs. Valid clinical reasons include a documented allergy to an inactive ingredient in Zepbound, a need for a dose or concentration not available in the standard pen, or a physical limitation that prevents the patient from using the autoinjector device.
• Patient-specific preparation only. The compound is prepared for that specific patient, not pre-made in bulk awaiting prescriptions. This is the fundamental distinction between 503A and 503B compounding.
• State licensing requirements apply.The compounding pharmacy must hold a valid 503A license in the patient's state. Availability varies by state because not all 503A pharmacies are licensed in all states.
• Cost is not a valid justification. This is a point that causes significant confusion. Under FDA guidance, the fact that Zepbound costs more than compounded tirzepatide is not, on its own, a sufficient medical necessity justification. The distinction must be clinical, not financial.

Platforms that have continued offering compounded tirzepatide in 2026 have built physician workflows that document individual patient need as part of the prescribing process. This adds clinical overhead, which is partly why pricing on these platforms has increased compared to the pre-March 2025 era.

What the Documentation Actually Looks Like

Physicians using the medical necessity model must produce contemporaneous chart documentation (not a checkboxed form) that addresses the specific clinical barrier. Three examples that satisfy this standard in practice:

• Excipient allergy example.Zepbound's single-dose pen contains polysorbate 80 as an inactive ingredient. A patient with a documented polysorbate 80 allergy (confirmed by prior reaction or allergy testing) cannot safely use the commercially available pen. A physician note reading "Patient has a documented allergy to polysorbate 80, a component of Zepbound autoinjector. Compounded tirzepatide without this excipient is medically necessary to avoid anaphylactoid risk" satisfies the 503A standard. The key is that the allergy must be documented in the medical record before the prescription is written, not added retroactively.
• Dose not commercially available.Zepbound is available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg pens. A patient who responds well at 3.5 mg but experiences intolerable side effects at 5 mg has a legitimate gap. A note documenting the clinical response at each titration step, plus the physician's clinical judgment that a 3.5 mg maintenance dose is appropriate, supports a compounding request for that specific strength.
• Autoinjector limitation.Patients with significant hand tremor, severe arthritis, or limited fine motor control may be clinically unable to use the Zepbound autoinjector reliably. A physician documenting the specific motor limitation and why a traditional vial-and-syringe compounded preparation better serves the patient's needs can support medical necessity compounding.

Platforms operating in this space typically require patients to complete a detailed intake questionnaire covering medical history, prior medication responses, allergies, and physical limitations before their physician drafts this documentation. The intake process takes longer than the pre-shortage era, where a simple weight and BMI check was sufficient to receive a prescription.

Compounding Pharmacies: 2026 Status

The pharmacy landscape shifted significantly after the March 2025 deadline. 503B outsourcing facilities, which had been producing tirzepatide at scale during the shortage, wound down production entirely. A subset of 503A pharmacies continue under the medical necessity model.

This table reflects publicly available information as of June 2026. Pharmacy availability changes frequently. Confirm current status directly with your telehealth provider.

Telehealth Platforms: Which Still Offer Compounded Tirzepatide

The platform landscape in 2026 splits into two groups: those that have transitioned to medical necessity documentation models and continue offering compounded tirzepatide, and those that discontinued it entirely and pivoted to compounded semaglutide.

Note: "Medical necessity attestation" means the platform has physicians document individual patient need as part of the prescribing workflow. This is a legitimate legal model but depends on good-faith clinical documentation.

For patients displaced from compounded tirzepatide programs, the most common paths are: (1) transitioning to compounded semaglutide through the same or a different platform, (2) seeking Zepbound through insurance if eligible, or (3) continuing tirzepatide through a platform using a medical necessity model. See Find GLP-1 providers in your state for current availability by state.

Your Alternatives to Compounded Tirzepatide

Displaced patients have three realistic paths forward. The right choice depends on your clinical situation, insurance coverage, and whether tirzepatide specifically or just effective GLP-1 therapy is your priority. For a full breakdown of the compounded versus FDA-approved question, see our guide to compounded vs. FDA-approved GLP-1 medications.

Option A: Compounded Semaglutide

Compounded semaglutide is the most accessible affordable GLP-1 option in 2026. Semaglutide (the active ingredient in Ozempic and Wegovy) remains on the FDA drug shortage list for certain strengths as of June 2026. That shortage designation keeps 503A compounding legal, and most GLP-1 telehealth platforms offer it at $99 to $249 per month. On average, tirzepatide produces slightly more weight loss than semaglutide: the SURMOUNT clinical trials showed approximately 20 to 22 percent body weight reduction for tirzepatide, compared to approximately 15 percent in the STEP trials for semaglutide. For most patients starting GLP-1 therapy, that difference is meaningful but not disqualifying for semaglutide. For patients already deep into tirzepatide therapy with strong response, the gap matters more.

Option B: Branded Zepbound

Branded Zepbound contains the same tirzepatide active ingredient as the compounded versions, with full FDA-approval, cGMP manufacturing, and established clinical trial data. The barrier is cost and access. Without insurance, Eli Lilly's self-pay vial program starts around $550 per month, more than double what most patients paid for compounded versions. With insurance and a successful prior authorization, copays typically fall in the $25 to $150 per month range depending on your plan. Prior authorization approval rates vary significantly by insurer and employer benefit design. For more on navigating this cost gap, see our guide to GLP-1 programs and insurance coverage.

Option C: Continue via Medical Necessity Model

If your current platform discontinued compounded tirzepatide, ask directly whether their physicians can document a medical necessity for your continued access. Platforms like Mochi Health and Brello Health currently accept patient transfers and have physician workflows built around this documentation model. The process takes longer and costs more than pre-March 2025 compounded tirzepatide, but it remains a viable path for patients with a genuine clinical case.

Are You a Candidate? A Decision Framework

Use this decision sequence to identify the right path for your situation.

1. Are you currently on compounded tirzepatide through a platform that discontinued it? If yes, you have three options: (1) ask your current platform about a medical necessity transition, (2) transfer to a platform like Mochi Health or Brello Health that still offers it, or (3) switch to compounded semaglutide through your current platform.
2. Have you never used tirzepatide but want to start? Compounded semaglutide is the most accessible and affordable entry point in 2026. Compounded tirzepatide via medical necessity model is possible but requires stronger clinical documentation and not all patients will qualify.
3. Do you have insurance that covers GLP-1 medications? Branded Zepbound is likely your best option. Work with your primary care physician or a GLP-1-focused telehealth platform to pursue prior authorization. Success rates depend on your specific plan.
4. Do you have a documented excipient allergy, need for a dose not commercially available, or a physician-documented reason Zepbound's autoinjector does not work for you? You are a candidate for medical necessity compounded tirzepatide. Bring that documentation to a platform like Mochi Health or Brello Health.
5. Are you primarily cost-driven with no specific clinical need for tirzepatide over semaglutide? Compounded semaglutide is widely available, similarly priced, and remains both a legal and effective option. Hims/Hers starts at $149 per month, and most other platforms come in under $249. Browse GLP-1 providers available in your state to compare current pricing and availability.

What to Expect When Switching from Tirzepatide to Semaglutide

For patients who were stable on compounded tirzepatide and are now transitioning to compounded semaglutide, the switch involves more than just swapping prescriptions. Tirzepatide and semaglutide have different receptor profiles: tirzepatide is a dual GIP/GLP-1 agonist, while semaglutide is a pure GLP-1 agonist. That distinction has practical consequences for patients switching between them.

Dose Equivalence: Not an Exact Science

There is no published FDA-approved dose conversion between the two drugs. However, based on clinical practice patterns observed across GLP-1 telehealth platforms, tirzepatide 5 mg roughly corresponds to semaglutide 1 mg in terms of GLP-1 receptor activation intensity, though individual response varies considerably. A patient who was stable on tirzepatide 7.5 mg might start semaglutide at 1 mg and titrate from there, rather than starting at the standard 0.25 mg initiation dose. Your prescribing physician should make this determination based on your response history, not a fixed formula.

First 4–6 Weeks: What Patients Report

Most patients switching from tirzepatide to semaglutide report a transition period of four to six weeks where the drug "feels different" in terms of appetite suppression and side-effect profile. Common patterns:

• Reduced appetite suppression in weeks 1–2.Tirzepatide's GIP component adds appetite suppression that pure GLP-1 agonists do not replicate. Some patients notice increased hunger in the first two weeks after switching before semaglutide equilibrates. This is normal and not a sign that semaglutide is not working.
• Nausea profile may differ. Semaglutide tends to produce more nausea in some patients compared to tirzepatide at equivalent clinical effect. Patients who were nausea-free on tirzepatide should start conservatively and titrate up only after four weeks at each dose level.
• Weight may stabilize or dip slightly before resuming loss. It is common for the scale to plateau for three to five weeks during the transition. This does not mean the new medication is ineffective. Meaningful weight loss typically resumes once the maintenance dose is established, usually by weeks six to eight.

Communicate weekly with your prescribing platform during the transition. Platforms with synchronous clinical support, like Mochi Health and Brello Health, are better suited for managing this kind of mid-treatment adjustment than platforms that operate primarily through asynchronous messaging.

Frequently Asked Questions